Heron Therapeutics Reveals APONVIE® (aprepitant) Injectable Emulsion Added to Updated Fifth Consensus Guidelines for Postoperative Nausea and Vomiting (PONV) Management
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 04 2025
0mins
Source: Yahoo Finance
APONVIE Overview: APONVIE is the only FDA-approved IV formulation of the NK-1 antagonist aprepitant, indicated for preventing postoperative nausea and vomiting (PONV) in adults, with a rapid onset and long half-life compared to oral alternatives.
Efficacy in PONV Prevention: Aprepitant, whether used alone or in combination with other therapies, significantly reduces the risk of PONV and is more effective than 5-HT3 receptor antagonists, making it a preferred choice for postoperative care.
Guidelines for Postoperative Care: The newly released PONV Guidelines emphasize the importance of long-acting antiemetics like APONVIE to mitigate post-discharge nausea and vomiting (PDNV), which affects a significant number of patients after surgery.
Clinical Implications: The guidelines advocate for a multimodal approach to PONV prevention, particularly for high-risk patients, highlighting the need for clinicians to be aware of and adhere to these recommendations to enhance patient recovery experiences.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HRTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HRTX
Wall Street analysts forecast HRTX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.387
Low
3.00
Averages
4.50
High
6.00
Current: 0.387
Low
3.00
Averages
4.50
High
6.00
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fulcrum, Heron, and MicroVision Stocks Plunge to Record Lows
- Fulcrum Drug Development Halted: Fulcrum Therapeutics saw its stock plunge over 51% to a 52-week low of $2.90 after announcing the discontinuation of its lead sickle cell disease drug pociredir due to FDA concerns about potential cancer risks, leading analysts to lower growth expectations and impacting the company's future prospects.
- Heron Patent Invalidated: Heron Therapeutics' shares fell to a record low of $0.44 following a federal court ruling that invalidated patents related to its cancer-supportive care drug CINVANTI, which could allow generic versions to enter the market sooner, prompting the CEO to announce an appeal and analysts to downgrade the stock to 'Hold'.
- MicroVision Reverse Stock Split Proposal: MicroVision's stock dropped nearly 32% to a 52-week low of $0.40 as the company sought shareholder approval for a reverse stock split proposal aimed at complying with Nasdaq's minimum bid-price requirement, which could significantly affect shareholder equity, while retail sentiment remained 'bearish'.
- Overall Market Reaction: Year-to-date, shares of FULC, HRTX, and MVIS have plunged between 50% and 72%, reflecting investor concerns over the core business prospects of these companies, although retail sentiment for Fulcrum on Stocktwits remains categorized as 'extremely bullish'.
See More
Heron Therapeutics Reports Q1 2026 Earnings with Mixed Results
- Revenue Growth Highlight: Heron Therapeutics reported net sales of $34.7 million in Q1 2026, with Acute Care revenue at $13.6 million and Oncology revenue at $21.1 million, reflecting a 32% year-over-year growth in the Acute Care portfolio, indicating resilience and potential in the market.
- Product Performance Analysis: ZYNRELEF and APONVIE contributed $10.2 million and $3.4 million respectively, with ZYNRELEF's unit volume growing by 111% under the IGNITE program, suggesting significant acceptance in targeted accounts and expected future sales growth.
- Financial Challenges: Despite revenue growth, the gross margin was only 69%, below the expected low to mid-70% range, with adjusted EBITDA at negative $727,000, reflecting the impact of severe weather on surgical volumes and rising costs, which may pose challenges to short-term profitability.
- Future Outlook: The company expects net product sales between $173 million and $183 million for 2026, with adjusted EBITDA projected at $10 million to $20 million, and despite short-term challenges, management remains optimistic about recovery driven by sales force expansion and the IGNITE program's momentum.
See More
Heron Therapeutics to Announce Q1 Earnings on May 11
- Earnings Announcement: Heron Therapeutics (HRTX) is set to release its Q1 2023 earnings report on May 11 before market open, with consensus EPS estimate at -$0.03 and revenue estimate at $36.72 million, reflecting a 5.6% year-over-year decline.
- Performance Expectations: Over the past year, HRTX has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, indicating a potential for continued improvement in profitability and revenue growth.
- Sales Target Outlook: The company has outlined ambitious sales targets for 2026, ranging from $173 million to $183 million, driven by momentum in acute care and expanded commercial investments, showcasing strategic growth initiatives.
- Market Performance Assessment: Despite mixed results in Q4, Heron Therapeutics is actively promoting its FY26 outlook, suggesting that its current position at the bottom of a trading range may present potential buying opportunities for investors.
See More
Heron Therapeutics to Host Q1 2026 Financial Results Conference Call
- Conference Call Announcement: Heron Therapeutics will host a conference call on May 11, 2026, at 8:30 a.m. ET to report its Q1 2026 financial results and discuss recent business highlights, aiming to provide transparent communication with investors.
- Participation Details: Participants can access the call via a registration link for dial-in details, and are encouraged to join 15 minutes early to avoid delays, reflecting the company's commitment to investor relations.
- Webcast Availability: The conference call will also be available via webcast on Heron's Investor Relations section of its website, with an archive of the teleconference and webcast accessible for 60 days post-call, allowing investors who cannot attend live to catch up.
- Company Overview: Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient lives through therapeutic innovations, leveraging advanced science and patented technologies to develop a portfolio aimed at enhancing the standard of care for acute and oncology patients.
See More
Heron (HRTX) Q4 2025 Earnings Call Transcript
See More
Heron Therapeutics Q4 2025 Earnings Highlights
- Successful Financing Completion: CEO Craig Collard emphasized the successful completion of financing, describing it as a 'meaningful derisking event' that allows the company to focus on commercial execution and product expansion, thereby driving sustained growth.
- Strong Financial Performance: Full-year net revenues for 2025 reached approximately $155 million, with adjusted EBITDA of $14.7 million, exceeding prior guidance of $9 million to $13 million, showcasing the company's financial robustness and growth potential.
- Acute Care Product Line Growth: ZYNRELEF achieved a 48% net revenue growth in Q4, while APONVIE grew by 97%, leading to an overall year-over-year increase of over 57% in the Acute Care franchise, indicating the company's strengthening competitive position in the market.
- Optimistic 2026 Outlook: Management raised the 2026 net product sales guidance to $173 million to $183 million, with expectations of EBITDA positivity, reflecting confidence in commercial expansion and the strategic necessity of targeted investments.
See More
Fulcrum, Heron, and MicroVision Stocks Plunge to Record Lows
- Fulcrum Drug Development Halted: Fulcrum Therapeutics saw its stock plunge over 51% to a 52-week low of $2.90 after announcing the discontinuation of its lead sickle cell disease drug pociredir due to FDA concerns about potential cancer risks, leading analysts to lower growth expectations and impacting the company's future prospects.
- Heron Patent Invalidated: Heron Therapeutics' shares fell to a record low of $0.44 following a federal court ruling that invalidated patents related to its cancer-supportive care drug CINVANTI, which could allow generic versions to enter the market sooner, prompting the CEO to announce an appeal and analysts to downgrade the stock to 'Hold'.
- MicroVision Reverse Stock Split Proposal: MicroVision's stock dropped nearly 32% to a 52-week low of $0.40 as the company sought shareholder approval for a reverse stock split proposal aimed at complying with Nasdaq's minimum bid-price requirement, which could significantly affect shareholder equity, while retail sentiment remained 'bearish'.
- Overall Market Reaction: Year-to-date, shares of FULC, HRTX, and MVIS have plunged between 50% and 72%, reflecting investor concerns over the core business prospects of these companies, although retail sentiment for Fulcrum on Stocktwits remains categorized as 'extremely bullish'.
See More
Heron Therapeutics Reports Q1 2026 Earnings with Mixed Results
- Revenue Growth Highlight: Heron Therapeutics reported net sales of $34.7 million in Q1 2026, with Acute Care revenue at $13.6 million and Oncology revenue at $21.1 million, reflecting a 32% year-over-year growth in the Acute Care portfolio, indicating resilience and potential in the market.
- Product Performance Analysis: ZYNRELEF and APONVIE contributed $10.2 million and $3.4 million respectively, with ZYNRELEF's unit volume growing by 111% under the IGNITE program, suggesting significant acceptance in targeted accounts and expected future sales growth.
- Financial Challenges: Despite revenue growth, the gross margin was only 69%, below the expected low to mid-70% range, with adjusted EBITDA at negative $727,000, reflecting the impact of severe weather on surgical volumes and rising costs, which may pose challenges to short-term profitability.
- Future Outlook: The company expects net product sales between $173 million and $183 million for 2026, with adjusted EBITDA projected at $10 million to $20 million, and despite short-term challenges, management remains optimistic about recovery driven by sales force expansion and the IGNITE program's momentum.
See More
Heron Therapeutics to Announce Q1 Earnings on May 11
- Earnings Announcement: Heron Therapeutics (HRTX) is set to release its Q1 2023 earnings report on May 11 before market open, with consensus EPS estimate at -$0.03 and revenue estimate at $36.72 million, reflecting a 5.6% year-over-year decline.
- Performance Expectations: Over the past year, HRTX has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, indicating a potential for continued improvement in profitability and revenue growth.
- Sales Target Outlook: The company has outlined ambitious sales targets for 2026, ranging from $173 million to $183 million, driven by momentum in acute care and expanded commercial investments, showcasing strategic growth initiatives.
- Market Performance Assessment: Despite mixed results in Q4, Heron Therapeutics is actively promoting its FY26 outlook, suggesting that its current position at the bottom of a trading range may present potential buying opportunities for investors.
See More
Heron Therapeutics to Host Q1 2026 Financial Results Conference Call
- Conference Call Announcement: Heron Therapeutics will host a conference call on May 11, 2026, at 8:30 a.m. ET to report its Q1 2026 financial results and discuss recent business highlights, aiming to provide transparent communication with investors.
- Participation Details: Participants can access the call via a registration link for dial-in details, and are encouraged to join 15 minutes early to avoid delays, reflecting the company's commitment to investor relations.
- Webcast Availability: The conference call will also be available via webcast on Heron's Investor Relations section of its website, with an archive of the teleconference and webcast accessible for 60 days post-call, allowing investors who cannot attend live to catch up.
- Company Overview: Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient lives through therapeutic innovations, leveraging advanced science and patented technologies to develop a portfolio aimed at enhancing the standard of care for acute and oncology patients.
See More
Heron (HRTX) Q4 2025 Earnings Call Transcript
See More
Heron Therapeutics Q4 2025 Earnings Highlights
- Successful Financing Completion: CEO Craig Collard emphasized the successful completion of financing, describing it as a 'meaningful derisking event' that allows the company to focus on commercial execution and product expansion, thereby driving sustained growth.
- Strong Financial Performance: Full-year net revenues for 2025 reached approximately $155 million, with adjusted EBITDA of $14.7 million, exceeding prior guidance of $9 million to $13 million, showcasing the company's financial robustness and growth potential.
- Acute Care Product Line Growth: ZYNRELEF achieved a 48% net revenue growth in Q4, while APONVIE grew by 97%, leading to an overall year-over-year increase of over 57% in the Acute Care franchise, indicating the company's strengthening competitive position in the market.
- Optimistic 2026 Outlook: Management raised the 2026 net product sales guidance to $173 million to $183 million, with expectations of EBITDA positivity, reflecting confidence in commercial expansion and the strategic necessity of targeted investments.
See More
